КЛЕТОЧНЫЙ ПРЕПАРАТ С ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ NKG2D В CAR T-ТЕРАПИИ РЕЦИДИВОВ/РЕФРАКТЕРНЫХ ОСТРЫХ МИЕЛОИДНЫХ ЛЕЙКОЗОВ И МИЕЛОДИСПЛАСТИЧЕСКОГО СИНДРОМА

Standard

КЛЕТОЧНЫЙ ПРЕПАРАТ С ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ NKG2D В CAR T-ТЕРАПИИ РЕЦИДИВОВ/РЕФРАКТЕРНЫХ ОСТРЫХ МИЕЛОИДНЫХ ЛЕЙКОЗОВ И МИЕЛОДИСПЛАСТИЧЕСКОГО СИНДРОМА. / Левчук, Ксения Александровна; Белоцерковская, Екатерина; Поздняков, Данила Юрьевич; Гиршова, Лариса; Зарицкий, А.Ю. ; Петухов, Алексей Вячеславович.

в: Klinicheskaya Onkogematologiya/Clinical Oncohematology, Том 14, № 1, 2021, стр. 138-148.

Результаты исследований: Научные публикации в периодических изданиях › Обзорная статья › Рецензирование

BibTeX

@article{427b51faaaed45a6b1893663999df6c8,

title = "КЛЕТОЧНЫЙ ПРЕПАРАТ С ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ NKG2D В CAR T-ТЕРАПИИ РЕЦИДИВОВ/РЕФРАКТЕРНЫХ ОСТРЫХ МИЕЛОИДНЫХ ЛЕЙКОЗОВ И МИЕЛОДИСПЛАСТИЧЕСКОГО СИНДРОМА",

abstract = "NK-cells as innate immunity elements manifest key reactions of antitumor immune response. NKG2D is an activating transmembrane receptor of NK-cells which is responsible for cytotoxicity initiation in response to the binding of specific ligands of genetically modified cells. Selective expression of NKG2D ligands provides a unique perspective on the therapy of wide variety of tumors. Acute myeloid leukemias (AML) are malignant hematological tumors with a high relapse risk. Due to the complexity of AML treatment strategy it is necessary to develop new approaches to tumor elimination using novel genetic constructs. Currently available CAR T-cell drugs with NKG2D receptor are successfully subjected to clinical studies in AML patients and prove their high therapeutic potential.",

keywords = "Acute myeloid leukemias, Adoptive therapy, Chimeric antigen receptor, NK-cells, NKG2D, Acute myeloid leukemias, Adoptive therapy, Chimeric antigen receptor, NK-cells, NKG2D",

author = "Левчук, {Ксения Александровна} and Екатерина Белоцерковская and Поздняков, {Данила Юрьевич} and Лариса Гиршова and А.Ю. Зарицкий and Петухов, {Алексей Вячеславович}",

year = "2021",

doi = "10.21320/2500-2139-2021-14-1-138-148",

language = "русский",

volume = "14",

pages = "138--148",

journal = "Klinicheskaya Onkogematologiya/Clinical Oncohematology",

issn = "1997-6933",

publisher = "ПРАКТИЧЕСКАЯ МЕДИЦИНА",

number = "1",

}

RIS

TY - JOUR

T1 - КЛЕТОЧНЫЙ ПРЕПАРАТ С ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ NKG2D В CAR T-ТЕРАПИИ РЕЦИДИВОВ/РЕФРАКТЕРНЫХ ОСТРЫХ МИЕЛОИДНЫХ ЛЕЙКОЗОВ И МИЕЛОДИСПЛАСТИЧЕСКОГО СИНДРОМА

AU - Левчук, Ксения Александровна

AU - Белоцерковская, Екатерина

AU - Поздняков, Данила Юрьевич

AU - Гиршова, Лариса

AU - Зарицкий, А.Ю.

AU - Петухов, Алексей Вячеславович

PY - 2021

Y1 - 2021

N2 - NK-cells as innate immunity elements manifest key reactions of antitumor immune response. NKG2D is an activating transmembrane receptor of NK-cells which is responsible for cytotoxicity initiation in response to the binding of specific ligands of genetically modified cells. Selective expression of NKG2D ligands provides a unique perspective on the therapy of wide variety of tumors. Acute myeloid leukemias (AML) are malignant hematological tumors with a high relapse risk. Due to the complexity of AML treatment strategy it is necessary to develop new approaches to tumor elimination using novel genetic constructs. Currently available CAR T-cell drugs with NKG2D receptor are successfully subjected to clinical studies in AML patients and prove their high therapeutic potential.

AB - NK-cells as innate immunity elements manifest key reactions of antitumor immune response. NKG2D is an activating transmembrane receptor of NK-cells which is responsible for cytotoxicity initiation in response to the binding of specific ligands of genetically modified cells. Selective expression of NKG2D ligands provides a unique perspective on the therapy of wide variety of tumors. Acute myeloid leukemias (AML) are malignant hematological tumors with a high relapse risk. Due to the complexity of AML treatment strategy it is necessary to develop new approaches to tumor elimination using novel genetic constructs. Currently available CAR T-cell drugs with NKG2D receptor are successfully subjected to clinical studies in AML patients and prove their high therapeutic potential.

KW - Acute myeloid leukemias

KW - Adoptive therapy

KW - Chimeric antigen receptor

KW - NK-cells

KW - NKG2D

KW - Acute myeloid leukemias

KW - Adoptive therapy

KW - Chimeric antigen receptor

KW - NK-cells

KW - NKG2D

UR - https://elibrary.ru/item.asp?id=44768995

UR - http://www.scopus.com/inward/record.url?scp=85109301732&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/ae167c7b-396c-3af2-b6f3-43ab8baccbda/

U2 - 10.21320/2500-2139-2021-14-1-138-148

DO - 10.21320/2500-2139-2021-14-1-138-148

M3 - Обзорная статья

VL - 14

SP - 138

EP - 148

JO - Klinicheskaya Onkogematologiya/Clinical Oncohematology

JF - Klinicheskaya Onkogematologiya/Clinical Oncohematology

SN - 1997-6933

IS - 1

ER -

ID: 84919741